Atyr Pharma INC Form 4 insider transactions

Director Timothy Coughlin of aTyr Pharma increased his holdings by purchasing 50,000 shares of common stock at an average price of $1.75 on May 30, 2024.

Jill Marie Broadfoot, CFO of aTyr Pharma, recently purchased 5,000 shares of the company's common stock at a price of $1.79 per share.

aTyr Pharma's CEO, Sanjay Shukla, recently purchased 20,000 shares of the company's common stock at an average price of $1.807 per share.

Director John K. Clarke acquired 24,000 stock options in aTyr Pharma, Inc. on May 22, 2024.

Director Jane A. Gross acquired 24,000 stock options in aTyr Pharma Inc. on May 22, 2024, according to a Form 4 filing with the SEC.

Director Svetlana Lucas acquired 24,000 stock options in aTyr Pharma on May 22, 2024, according to a Form 4 filing.

Paul Schimmel, a director of aTyr Pharma Inc., acquired 24,000 stock options on May 22, 2024, according to a Form 4 filing with the SEC.

Director Sara Zaknoen acquired 24,000 stock options in aTyr Pharma, Inc. on May 22, 2024.

Director Timothy Coughlin acquired 24,000 stock options in aTyr Pharma, Inc. on May 22, 2024, according to a Form 4 filing with the SEC.